BioCentury
ARTICLE | Clinical News

Novartis reports response data for CAR T in DLBCL

June 8, 2017 12:34 AM UTC

Novartis AG (NYSE:NVS; SIX:NOVN) said chimeric antigen receptor (CAR) T cell therapy tisagenlecleucel-T (CTL019) led to a best overall response rate (ORR) of 59% in the pivotal Phase II JULIET trial to treat relapsed or refractory diffuse large B cell lymphoma. The interim data were released in an abstract ahead of next week's International Conference on Malignant Lymphoma in Lugano.

Tisagenlecleucel-T led to a 43% complete response rate and a 16% partial response rate. The three-month ORR was 45%, including complete and partial response rates of 37% and 8%, respectively. The analysis included 51 patients with at least three months of follow-up or earlier discontinuation who received a single infusion of tisagenlecleucel-T following restaging, bridging therapy and lymphodepleting chemotherapy. Sixty percent of patients received three or more lines of chemotherapy and 51% had a prior autologous stem cell transplantation (ASCT)...

BCIQ Company Profiles

Kite Pharma Inc.

Novartis AG

BCIQ Target Profiles

CD19